Latest Funding News

Commonwealth Bank of Australia reported a stable $2.6 billion cash profit for the quarter, maintaining strong capital and dividend payouts despite slight increases in consumer arrears and corporate credit risks.

Peak Rare Earths Limited has voluntarily suspended trading of its shares pending a significant announcement on potential corporate and capital raising transactions expected by 16 May 2025.

US Masters Residential Property Group reported solid Q1 2025 sales of US$48.07 million and a 5% rise in net operating income, while reducing senior debt by over US$31 million despite ongoing market volatility.

Highfield Resources Limited has had its ASX trading suspension lifted immediately following a key announcement on its funding arrangements, signaling renewed market confidence.

Highfield Resources has inked a non-binding letter of intent with Qinghai Salt Lake, a China Minmetals subsidiary, for a US$300 million equity investment aimed at fast-tracking its potash projects in Spain and Canada.

Highfield Resources has obtained a standby loan facility from EMR Capital to support its operations and strategic transaction progress, including advancing its flagship Muga Project. The company also extended the maturity of its convertible loan notes, underscoring ongoing investor confidence during a pivotal phase.

Infinity Mining Limited has successfully closed a pro-rata entitlement issue, raising over $280,000 through new options set to be listed on the ASX next week.

Nanoveu Limited has increased its capital raise by $310,000, bringing the total placement to $3.02 million, with updated details on share and option issuances including conditional allocations to its Executive Chairman.

Clean Seas Seafood Limited has entered a binding scheme of arrangement with Yumbah Aquaculture, offering shareholders a 52% premium cash exit or a speculative scrip alternative. The Independent Board Committee recommends approval, with a shareholder meeting set for June 23.

Neuren Pharmaceuticals has received official FDA minutes confirming the primary endpoints for its pivotal Phase 3 trial of NNZ-2591 targeting Phelan-McDermid syndrome, reinforcing the positive signals from earlier studies.

Marimaca Copper Corp reported a net loss of $2.25 million for Q1 2025, maintaining solid liquidity while managing risks tied to a significant receivable under liquidation proceedings.

Life360, Inc. reported a strong Q1 2025 with 32% revenue growth to $103.6 million, driven by a 33% increase in subscription revenue and a return to profitability with $4.4 million net income. The company also advanced its strategic positioning through a $4.5 million acquisition and a key partnership.